# A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

> **NCT02244112** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 43 (actual)

## Conditions studied

- Advanced Non-Central Nervous System (CNS) Malignancies

## Interventions

- **DRUG:** Oprozomib
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT02244112
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2015-05-15
- **Final completion:** 2019-07-10
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Why study stopped revised to "A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ009 was halted
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244112, "A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02244112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*